Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rezpegaldesleukin (Primary)
Indications Systemic lupus erythematosus
Focus Therapeutic Use
Acronyms ISLAND; ISLAND-SLE
Sponsors Eli Lilly and Company; Nektar Therapeutics

Most Recent Events

12 Apr 2023 Status changed from active, no longer recruiting to completed.
30 Mar 2023 This trial has been completed in Czechia (End Date: 16 Feb 2023), according to European Clinical Trials Database record.
23 Feb 2023 Primary endpoint (Percentage of Participants who Achieve a 4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score) has not been met, according to a Nektar Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com